Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment.
星期二，Merck（纽交所：MRK）发布了HERTHENA-Lung02第3期试验patritumab deruxtecan在先前接受了EGFR酪氨酸激酶抑制剂（TKI）治疗的局部晚期或转移性EGFR突变非小细胞肺癌（NSCLC）患者中的顶线数据。
The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
该研究达到了无进展生存期（PFS）的主要终点，patritumab deruxtecan相比铂金加pemetrexed诱导化疗后的pemetrexed维持化疗在统计学上显示出显著改善。
Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs.
尽管政府谈判，美国人可能仍然不得不为处方药支付更多费用。
Overall survival (OS) data were immature at the time of the analysis, and the trial will continue to assess OS, a secondary endpoint.
在分析时，总生存期（OS）数据尚不成熟，试验将继续评估OS作为一个次要终点。
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:DSNKY) and being jointly developed by Daiichi Sankyo and Merck.
Patritumab deruxtecan是一种由大塚制药（场外交易：DSNKY）发现并与默克共同开发的具有特殊设计的以HER3为靶的DXd抗体药物联苯胺（ADC）。
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.
HERTHENA-Lung02中观察到的安全性与先前肺癌临床试验中观察到的patritumab deruxtecan的安全性相一致，没有发现新的安全信号。
The majority of interstitial lung disease (ILD) events were low-grade (grades 1 and 2). Two grade 5 ILD events were observed.
大多数间质性肺疾病（ILD）事件为低度（1级和2级）。观察到两个5级ILD事件。
Recently, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
最近，Summit Therapeutics Inc.（纳斯达克：SMMT）发布了在中国由合作伙伴Akeso, Inc赞助的ivonescimab第3期HARMONi-2试验的初步分析结果。
The trial evaluated monotherapy ivonescimab against Merck's Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression.
该试验评估了单药ivonescimab与Merck的Keytruda（pembrolizumab）在局部晚期或转移性非小细胞肺癌患者中，其肿瘤具有阳性PD-L1表达。
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial's primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51.
ivonescimab单药在该试验的主要终点——无进展生存期方面显示出了显著的改善，相比单药pembrolizumab，达到了0.51的风险比。
Price Action: MRK stock is up 0.39% at $118.42 during the premarket session at last check Tuesday.
股票行情: MRk股价于周二盘前交易时段上涨0.39%，报收于118.42美元。
- EssilorLuxottica And Meta Platforms Double Down On Smart Eyewear: Details.
- EssilorLuxottica和meta platforms加倍推动智能眼镜：详细信息。